Log In
BCIQ
Print this Print this
 

NVB302

  Manage Alerts
Collapse Summary General Information
Company Novacta Biosystems Ltd.
DescriptionType B lantibiotic (lanthionine-containing antibiotics)
Molecular Target
Mechanism of Action 
Therapeutic Modality 
Latest Stage of DevelopmentPhase I
Standard IndicationClostridium
Indication DetailsTreat hospital-acquired Clostridium difficile infection (CDI)
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today